Tsai Katy K, Zarzoso Inés, Daud Adil I
a University of California San Francisco ; San Francisco , CA USA.
Hum Vaccin Immunother. 2014;10(11):3111-6. doi: 10.4161/21645515.2014.983409.
Melanoma is the most serious form of skin cancer. Metastatic melanoma historically carries a poor prognosis and until recently there have been few effective agents available to treat widely disseminated disease. Recognition of the immunogenic nature of melanoma has resulted in the development of various immunotherapeutic approaches, especially with regards to the programmed cell death 1 (PD-1) receptor and its ligand (PD-L1). Antibodies targeting the PD-1 axis have shown enormous potential in the treatment of metastatic melanoma. Here, we will review the immune basis for the disease and discuss approved immunotherapeutic options for advanced melanoma, as well as the current state of development of PD-1 and PD-L1 antibodies and their importance in shaping the future of melanoma treatment.
黑色素瘤是最严重的皮肤癌形式。转移性黑色素瘤历来预后较差，直到最近，治疗广泛播散性疾病的有效药物仍很少。对黑色素瘤免疫原性本质的认识促使了各种免疫治疗方法的发展，尤其是针对程序性细胞死亡1（PD-1）受体及其配体（PD-L1）的方法。靶向PD-1轴的抗体在转移性黑色素瘤治疗中显示出巨大潜力。在此，我们将回顾该疾病的免疫基础，讨论晚期黑色素瘤已获批的免疫治疗选择，以及PD-1和PD-L1抗体的当前研发状况及其在塑造黑色素瘤治疗未来方面的重要性。
